Back to companies

Mersana Therapeutics Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Mersana Therapeutics Inc (Mersana) is a pharmaceutical company. The company develops antibody-drug conjugates (ADC) for the treatment of cancer. Its pipeline product XMT-1536, XMT-1660, XMT-2560, and XMT-1592, an ADC which targets sodium-dependent phosphate transport protein NaPi2b utilizing Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

Headquarters United States of America

Address 840 Memorial Dr, Cambridge, Massachusetts, 02139-3789


Telephone 1 617 4980020

No of Employees 169

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange MRSN (NASD)

Revenue (2021) $43,000 -94.8% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -93.2% (2021 vs 2020)

Market Cap* $444.2M

Net Profit Margin (2021) XXX -3,619.3% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Mersana Therapeutics Inc’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate Mersana Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Mersana Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

10+

Clinical Trials

Determine Mersana Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
XMT-1536
XMT-1660
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In June, the company announced an authorized sub-committee of the Compensation Committee of the Board of Directors granted inducement awards to purchase an aggregate of 104,475 shares of its common stock and restricted stock unit awards (RSUs) to acquire an aggregate of 72,600 shares of its common stock,
2022 Regulatory Approval In May, the company secured the FDA grant of Orphan Drug Designation to XMT-2056 for the treatment of gastric cancer.
2022 Contracts/Agreements In February, the company announced a research collaboration and license agreement with Janssen Biotech, Inc to discover novel ADCs for three targets.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Mersana Therapeutics Inc Endonovo Therapeutics Inc Aprea Therapeutics Inc Cavion LLC Odonate Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Cambridge Woodland Hills Boston Charlottesville New York
State/Province Massachusetts California Massachusetts Virginia New York
No. of Employees 169 - 16 - 137
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
David Mott Chairman Executive Board 2012 55
Anna Protopapas Chief Executive Officer; Director; President Executive Board 2015 56
Brian C. DeSchuytner Senior Vice President; Chief Financial Officer Senior Management 2021 -
Timothy B. Lowinger Chief Technology Officer; Chief Scientific Officer Senior Management 2019 57
Alejandra Carvajal Chief Legal Officer; Senior Vice President Senior Management 2021 47
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer